Dyadic International Inc. (DYAI) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Dyadic International, Inc. on June 3, 2021, reporting events occurring on May 28, 2021. The Company is a Delaware corporation focused on developing a COVID-19 vaccine candidate, DYAI-100, based on the SARS-CoV-2 receptor binding domain (RBD).
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a material definitive agreement and does not contain financial statements or performance metrics.
Material Changes
On May 28, 2021, Dyadic International (USA), Inc., a subsidiary of the Company, entered into an amendment to its Master Services Agreement (MSA) with CR2O B.V. ("CR2O"). Key details include:
- Agreement Scope: The Amended MSA restates the engagement for CR2O to oversee and perform pre-clinical and clinical trial services for the DYAI-100 vaccine candidate.
- Work Order: Work Order Number 02 was executed on the same date, authorizing additional pre-clinical trial services.
- Effective Date: The agreement is effective retroactively to March 18, 2021.
- Term: The MSA term is five years from the Effective Date.
- Strategic Goal: These services support the Company's progression toward an anticipated Phase 1 clinical trial.
Guidance, Outlook, and Risks
Management commentary indicates the Company is moving toward an anticipated Phase 1 clinical trial for DYAI-100. The filing does not provide specific financial guidance, risk factors, or contingencies beyond the standard incorporation of the agreement terms by reference. The full terms of the MSA and Work Order are filed as Exhibit 10.1, with certain specific items redacted.
Investor Verification Checklist
- Review Exhibit 10.1 to understand the redacted terms and specific financial obligations within the Amended MSA and Work Order 02.
- Verify the timeline and milestones for the anticipated Phase 1 clinical trial for DYAI-100.
- Confirm the total cost and payment schedule associated with the services provided by CR2O B.V.
- Monitor subsequent filings for updates on the status of the pre-clinical and clinical trials.